MODERATE
57
The Alpha Score is an informational signal based on public SEC fillings. It is not investment advice.
CEOJOURNAL SIGNAL SUMMARY·GENERATED FROM PUBLIC SEC FILINGS
Leon O Moulder Jr made an open-market purchase of Zenas Biopharma, Inc. on 2026-05-18, investing approximately $1,012,800. This is a CEOJournal signal summary placeholder — full narrative pending Claude Haiku enrichment.
Summary based on Form 4 filings and DEF 14A proxy data. Not investment advice. Updated on new filing activity.
Score Components
COMPOSITE ALPHA SCORE
57
Score calculated from open-market purchases only; 10b5-1 preplanned trades excluded; not investment advice.
OPPORTUNISM
Proxy from ownership-change magnitude. Real Opportunism signal will use %52W proximity once price data is in pipeline.
CONVICTION
Log-scaled from trade size. Real Conviction signal will use trade $ ÷ total compensation once DEF 14A data is in pipeline.
PATTERN
Placeholder — 90-day qualifying buy count requires historical Form 4 scrapes (Phase 2).
CLUSTER
Count of other insiders buying the same ticker in our current dataset window.
TRACK RECORD
Placeholder — executive tenure × prior buy P&L requires historical price tracking (Phase 2).
FORM 4 TRANSACTION HISTORYSOURCE: SEC EDGAR
| DATE | TRANSACTION TYPE | CODE | SHARES | PRICE | TOTAL VALUE | 10b5-1 | SCORE |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | Open-Market Purchase | P | 60,000 | $16.88 | $1,012,800 | N/A | 57 |
Data sourced from SEC EDGAR Form 4 filings, updated within 24 hours.
Only transaction code P (open-market purchase) qualifies for Alpha Score calculation.
Only transaction code P (open-market purchase) qualifies for Alpha Score calculation.
EXECUTIVE PROFILE
Leon O Moulder Jr
CEO
Leon O. Moulder, Jr. has served as Chief Executive Officer of Zenas Biopharma, Inc. since August 2023 and as Chairman of the Board of Directors since 2020. He is the Founder of the company and has been the Managing Member of Tellus BioVentures, LLC since March 2019. Prior to Zenas, he co-founded TESARO, Inc., where he served as CEO until its acquisition by GlaxoSmithKline in January 2019. Moulder has also held leadership roles at Abraxis BioScience Inc. and Eisai Corporation of North America.
EDUCATION
- Temple University (Pharmacy)
- The University of Chicago Booth School of Business (M.B.A.)
BOARD SEATS
- Zai Lab Ltd. · Board Member
- Trevena, Inc. · Board Member
- Dianthus · Board Member
COMPENSATION & OWNERSHIP ·SOURCE: DEF 14A PROXY
ANNUAL BASE SALARY
$520,000
TOTAL COMPENSATION
$4,661,000
SHARES HELD
2,306,122
EST. HOLDINGS VALUE
$42.43M
as of May 30, 2026 close
Summary based on Form 4 filings and DEF 14A proxy data. Not investment advice. Updated on new filing activity.
RELATED SIGNALS